Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Joly-Lobbedez, Florence
20  Ergebnisse:
Personensuche X
?
1

A Double-Blind, Randomized Phase II Study to Evaluate the S..:

Campone, Mario ; Berton-Rigaud, Dominique ; Joly-Lobbedez, Florence...
The Oncologist.  18 (2013)  11 - p. 1190-1191 , 2013
Link: https://doi.org/10.1634/..
 
?
2

A double-blind, randomized phase II study to evaluate the s..:

Campone, Mario ; Berton-Rigaud, Dominique ; Joly-Lobbedez, Florence...
boreal:154933.  , 2013
Link: http://hdl.handle.net/20..
 
?
3

A double-blind, randomized phase II study to evaluate the s..:

Campone, Mario ; Berton-Rigaud, Dominique ; Joly-Lobbedez, Florence...
boreal:154933.  , 2013
Link: http://hdl.handle.net/20..
 
?
4

A Double-Blind, Randomized Phase II Study to Evaluate the S..:

Campone, Mario ; Berton-Rigaud, Dominique ; Joly-Lobbedez, Florence...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825303.  , 2013
Link: http://www.ncbi.nlm.nih...
 
?
5

Supplementary Table S6 from Atezolizumab plus Magrolimab, N..:

Alexandra Drakaki ; Thomas Powles ; Aristotelis Bamias...
doi:10.1158/1078-0432.24473254.v1.  , 2023
Link: https://doi.org/10.1158/..
 
?
6

Supplementary Figure S1 from Atezolizumab plus Magrolimab, ..:

Alexandra Drakaki ; Thomas Powles ; Aristotelis Bamias...
doi:10.1158/1078-0432.24473281.v1.  , 2023
Link: https://doi.org/10.1158/..
 
?
7

Supplementary Figure S4 from Atezolizumab plus Magrolimab, ..:

Alexandra Drakaki ; Thomas Powles ; Aristotelis Bamias...
doi:10.1158/1078-0432.24473272.v1.  , 2023
Link: https://doi.org/10.1158/..
 
?
8

Supplementary Table S4 from Atezolizumab plus Magrolimab, N..:

Alexandra Drakaki ; Thomas Powles ; Aristotelis Bamias...
doi:10.1158/1078-0432.24473260.v1.  , 2023
Link: https://doi.org/10.1158/..
 
?
9

Supplementary Table S7 from Atezolizumab plus Magrolimab, N..:

Alexandra Drakaki ; Thomas Powles ; Aristotelis Bamias...
doi:10.1158/1078-0432.24473251.v1.  , 2023
Link: https://doi.org/10.1158/..
 
?
10

Supplementary Table S2 from Atezolizumab plus Magrolimab, N..:

Alexandra Drakaki ; Thomas Powles ; Aristotelis Bamias...
doi:10.1158/1078-0432.24473266.v1.  , 2023
Link: https://doi.org/10.1158/..
 
?
11

Supplementary Figure S2 from Atezolizumab plus Magrolimab, ..:

Alexandra Drakaki ; Thomas Powles ; Aristotelis Bamias...
doi:10.1158/1078-0432.24473278.v1.  , 2023
Link: https://doi.org/10.1158/..
 
?
12

Supplementary Table S5 from Atezolizumab plus Magrolimab, N..:

Alexandra Drakaki ; Thomas Powles ; Aristotelis Bamias...
doi:10.1158/1078-0432.24473257.v1.  , 2023
Link: https://doi.org/10.1158/..
 
?
13

Supplementary Figure S3 from Atezolizumab plus Magrolimab, ..:

Alexandra Drakaki ; Thomas Powles ; Aristotelis Bamias...
doi:10.1158/1078-0432.24473275.v1.  , 2023
Link: https://doi.org/10.1158/..
 
?
14

Supplementary Table S1 from Atezolizumab plus Magrolimab, N..:

Alexandra Drakaki ; Thomas Powles ; Aristotelis Bamias...
doi:10.1158/1078-0432.24473269.v1.  , 2023
Link: https://doi.org/10.1158/..
 
?
15

Supplementary Table S3 from Atezolizumab plus Magrolimab, N..:

Alexandra Drakaki ; Thomas Powles ; Aristotelis Bamias...
doi:10.1158/1078-0432.24473263.v1.  , 2023
Link: https://doi.org/10.1158/..
 
1-15